Free Trial
NASDAQ:TSBX

Turnstone Biologics Q4 2024 Earnings Report

Turnstone Biologics logo
$0.36 0.00 (0.00%)
As of 08/11/2025

Turnstone Biologics EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.69
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Turnstone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Turnstone Biologics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 28, 2025
Conference Call Time
7:00PM ET

Turnstone Biologics Earnings Headlines

Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …tc pixel
See More Turnstone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Turnstone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Turnstone Biologics and other key companies, straight to your email.

About Turnstone Biologics

Turnstone Biologics (NASDAQ:TSBX), a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

View Turnstone Biologics Profile

More Earnings Resources from MarketBeat